The Danish pharma giant tested monlunabant, a drug it acquired in 2023 with its $1 billion purchase of Inversago Pharma, in a phase 2 trial involving 243 participants with obesity and other ...

“We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-adjusted weight loss at 16 weeks, which we see as broadly supportive of the mechanism ...

Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.

CRB-913 demonstrated a wide dose response weight loss curve in DIO mice ranging from 5 mg/kg/day to 80 mg/kg/day with no plateauing effect and reaching a weight loss of 31% by day 19. Extending the ...

The news item from Novo Nordisk that was so impactful was the readout from a clinical trial of monlunabant, an investigational treatment it's testing for obesity. In a phase 2a clinical trial ...

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1 ...

“We are encouraged to see that monlunabant met its primary endpoint and demonstrated at least a 6% placebo-adjusted weight loss at 16 weeks, which we see as broadly supportive of the mechanism of ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment ...

Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After 16 ...